Metabolic-hydroxy and carboxy functionalization of alkyl moieties in drug molecules: Prediction of structure influence and pharmacologic activity

Babiker M. El-Haj*, Samrein B.M. Ahmed

1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, UAE; b.elhag.ajman.ac.ae
2. College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, UAE; samahmed@sharjah.ac.ae

Abstract: Alkyl moieties—open chain or cyclic—are common in drug molecules and can be internal or terminal. The open-chain alkyls can be linear or branched; the cyclic alkyls may be substituted. Usually, the branches in open-chain alkyls and substituents in cycloalkyls influence both the pharmacokinetics and pharmacodynamics of a drug molecule. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some parent-drug equiactive hydroxy metabolites have been developed into metabolite ester prodrugs, while some of the parent-drug carboxy metabolites have been developed into metabolite drugs. In this review, we present and discuss the above state of affairs for a variety of drug classes, using selected drug members to show the effect on pharmacologic activity as well as dependence of the metabolic change on drug molecular structure. Some subtexts found to manifest from the hydroxy and carboxy functionalization of alkyl moieties in drug molecules are presented and discussed. The review provides basis for informed predictions of (i) structural features required for metabolic hydroxy and carboxy functionalization of alkyl moieties in existing or planned small drug molecules; and (ii) whether the resulting metabolites will possess pharmacologic activity or be devoid of it.

Keywords: Metabolic functionalization of alkyl moieties in drug molecules; structure influence on metabolic functionalization of alkyl moieties; mechanism of alkyl free radical hydroxy functionalization; pharmacologic activity of hydroxy and carboxy functionalized alkyl moieties in drug molecules; primary and auxiliary pharmacophores; auxophores

Presentation of Data

The review falls in four sections: introduction, results, discussion and conclusion. The survey data for each member of the selected class of drugs include the following: a brief introduction discussing pharmacological action and mechanism, major metabolic pathways described textually and diagrammatically, and relevant stereochemistry. As a space-saving strategy, and when
appropriate, the diagrammatic metabolic pathways will highlight only the part of the drug molecule where the metabolic change occurs. Chiral centers in the drug or metabolite molecules are indicated by asterisks (*); dots indicate free radicals. The figures also include the enzymes involved in the metabolism of the case drugs as well as the percentages of metabolites subject to availability in the literature. Only drugs for which the pharmacologic activities of the metabolites are reported are included. An illustrative approach has been adopted to make the figures semi-standalone sources of information in conjunction with the accompanying text. Individual drug cases will be discussed as they are presented while classes of drugs will be discussed in Section 3. Some general and specific topics that have manifested from the hydroxy and carboxy functionalization of alkyl moieties need to be highlighted for extra information. These topics are presented and discussed in Section 3.

1. Introduction

Nonpolar alkyl moieties are frequently incorporated into drug molecules to serve pharmacodynamic and/or pharmacokinetic purposes. Being lipophilic, alkyl moieties are metabolized in phase I via hydroxy functionalization to alcohols—a process which is, in some cases, followed by carboxy functionalization. Usually, the carboxyl and sterically unhindered hydroxyl groups in the resulting metabolites are conjugated in phase II by glucuronic acid. The chemical forms and metabolic products of the alkyl moieties surveyed in this review are summarized in Table 1. In addition, the following topics will be discussed in the introduction section:

- Mechanism of alkyl moiety hydroxylation
- Prevalence of intrinsic and metabolically-formed carboxyl groups in drug molecules
- Binding interactions of alkyl and hydroxyl groups with receptors
- Stereoselective metabolic hydroxylation of alicycles in drug molecules

Table 1. Alkyl moieties metabolized by hydroxy and carboxy functionalization.

| Aliphatic moieties metabolized by oxidative hydroxylation | Metabolic products |
|---------------------------------------------------------|--------------------|
| Alkyl (linear or branched)                              | Primary, secondary, or tertiary alcohols, depending on the class of substrate carbon; primary alcohols are further oxidized to carboxylic acids |
| Unhindered methylene groups in alicycles and aliphatic heterocycles (usually at the farthest position from the monosubstituent) | Secondary alcohols |
| Benzylic methyl groups                                   | Primary alcohols, followed by oxidation to carboxyl group |
| Methyl groups bonded to alicycles or heterocycles        | Primary alcohols, followed by oxidation to carboxyl groups |
Methylene groups alpha to both carbonyl and imino groups | Secondary alcohols
---|---
Allylic carbons | Primary alcohols in open-chain alkyls and secondary alcohols in alicycles

In drug molecules, alkyl moieties usually extend from one carbon (methyl, CH\(_3\)) to four carbons (butyl, C\(_4\)H\(_x\)). Methyl groups are the most common. Higher-carbon linear alkyl groups, such as pentyl and hexyl, are sometimes encountered. Alkyl moieties in drug molecules can be internal or terminal. In linear terminal alkyl chains with more than one carbon atom, the carbon of the ultimate methyl group is designated as omega (ω), whereas the carbon prior to it is called the penultimate and designated as ω-1. Common internal alkyl moieties in drug molecules are ethylene, propylene, and butylene, which may be straight chain or may have short alkyl or other group branches. The most commonly encountered terminal branched alkyl groups are isopropyl, isobutyl, and tertiary butyl. The methyl group is also found attached to rings, which may be aromatic (where the carbon of the methyl group is benzylic) or alicyclic.

Alkyls (open chain or cyclic) are mostly hydrophobic in nature. They are found in drug molecules in their capacity as functional groups or as frameworks for (or carriers of) hydrophilic or other hydrophobic functional groups. Usually, internal linear alkyls assume the role of frameworks, while ω methyls of terminal linear or branched alkyls assume primary or auxiliary pharmacophoric roles by interacting with biological targets through van der Waals binding. In addition, internal linear alkyls may be used as spacers between functional groups for different purposes—mainly to extend the chain for one of the functional groups to reach a binding site. All the above alkyls are illustrated in Figure 1. Generally, branching of alkyl chains results in compactness: this feature will cause less disruption of the hydrogen-bonding network of water. Consequently, the lipophilicity of the drug containing the branched alkyl group will decrease, and if the drug’s mechanism of action is related to its lipophilicity, then a significant alteration in the biologic effect will result. Further, as functional groups, alkyls and alicycles, interact with amino-acid moieties in enzyme- or receptor-active cavities through van der Waal’s forces of attraction in hydrophobic pockets. In contrast to ω-methyls in terminal linear chains, bulky, branched alkyls allow for determining the depth and width of the hydrophobic pocket.

Furthermore, alicyclic groups encountered in drug molecules extend from cyclopropyl to cyclooctyl, with cyclohexyl being the most common. Generally, alicycles smaller than cyclohexyl suffer from ring strain and hence of low stability while larger alicycles than cyclohexyl pose steric effects, which may be detrimental to the interaction with hydrophobic pockets in receptors. The alkyl moieties in alicycles and aliphatic heterocycles are the methylene groups.

Metabolic hydroxy functionalization of alkyls (open chain or cyclic) will modify their interactions with other groups through hydrogen-bond-dipole, ion-hydrogen bond, and hydrogen-bond-induced-dipole bindings with expected effects on the drug’s pharmacodynamics and pharmacokinetics. On the other hand, carboxy functionalization of alkyls will modify their interactions—mainly by ion-ion and ion-dipole bindings. The interaction of alkyls (as well as hydroxyl and carboxyl groups) in their pharmacophoric capacity with biological targets is depicted in Figure 2.
Mechanism of Metabolic Oxidation of Alkyl Moieties

Metabolic hydroxylation of alkyl groups is catalyzed by a family of monooxygenase enzymes, known as the “cytochrome P450” family, that contain heme redox centers. The heme group is characterized by an iron atom coordinated to the nitrogen atoms of four linked pyrrole rings. The mechanism of metabolic hydroxylation involves free-radical formation at the substrate carbon in the alkyl moiety, as illustrated in Figure 3[1–3]. In drug molecules containing more than one class of carbon atoms, the priority of metabolic hydroxylation is dictated by the stability of the intermediate free radicals; however, anomalies may occur due to prevailing electronic or steric effects in the molecule. Due to electronic effects, the stability of alkyl free radicals follows this sequence: (benzyl, allyl > 3° > 2° > 1° > methyl). The different classes of alkyl carbons are shown in Figure 1.

Figure 1. Alkyl moieties encountered in drug molecules.

Figure 2. Bindings of alkyl hydroxy and carboxyl groups to biological targets.

The radical initiator abstracts a hydrogen from the alkyl substrate to form a free radical.

Figure 3. Free-radical metabolic alkyl hydroxylation (adapted from reference 3).
Alicycles and aliphatic heterocycles are often used in drug molecules in place of open-chain alkyls to restrict flexibility and rotation. This restriction will lead to changes in conformation and hence alteration of the spatial relationship between the pharmacophoric (functional) groups in the molecule. The ultimate effect is a change in the interactions with the biologic target. Alicycles and aliphatic heterocycles are metabolized by methylene (-CH₂-) hydroxylation via the free-radical mechanism depicted in Figure 3. In monosubstituted cyclohexyl groups—the most common in drug molecules—the metabolic hydroxylation is stereoselective, favoring the trans isomer for its higher stability with respect to the cis isomer (Figure 4). As will be discussed in due course, stereoselectivity also extends to pharmacologic activity.

Figure 4. Stereoselective metabolic oxidation of monosubstituted cyclohexyl moiety.

Carboxyl functional groups are intrinsic to drug molecules of various pharmacological classes and are usually metabolized in phase II by glucuronic acid conjugation. Examples of drugs containing intrinsic carboxy groups in primary pharmacophoric settings include the COX1/COX2-inhibitor NSAIDS, the ACE inhibitors (the prils), the antibacterial fluoroquinolones, the statins (antihyperlipidemic drugs), and neuraminidase inhibitors (anti-influenza drugs). Examples of drugs containing intrinsic carboxy groups as auxiliary pharmacophores include the β-lactam antibiotics (penicillins and cephalosporins). Intrinsic carboxyl groups in drug molecules usually form sites of prodrug formation upon esterification.

In the body, carboxyl groups are formed metabolically in four ways:

a. oxidation of primary alcoholic groups, either intrinsic to the drug molecule or metabolically produced
b. oxidation of alkyl-chain ω methyl groups
c. oxidation of benzylic methyl groups or methyl groups bonded to alicycles or heterocycles
d. oxidation of nitrile (CN) groups
e. hydrolysis of ester (or amide) groups

Routes (b) and (c) usually occur via the sequential formation of primary alcohol and aldehyde intermediates. As long as they remain unconjugated, intrinsically-existing or metabolically-formed carboxyl groups are completely ionized at the physiologic pH of 7.4, and as such, they interact with other groups in receptors (or solvents) through ion-pairing or ion-dipole bindings.

Since carboxy metabolites mostly follow from the oxidation of intrinsic or metabolically formed primary alcoholic groups, the association sufficiently warrants a parallel discussion of alcoholic and carboxy metabolites.

2. Results

Alcoholic and Carboxy Metabolites Resulting from Alkyl Moiety Oxidation and Carboxy Metabolites Resulting from Intrinsic Hydroxymethyl Group Oxidation

The selection of drug candidates for metabolic alkyl-moiety hydroxylation and carboxyl functionalization was based on the presence of the groups in Table 1.
Representative drugs from different chemical and pharmacological classes containing the groups given in Table 1 include the followings:

- The NSAID ibuprofen, which contains an isobutyl group attached to a benzene ring (Figure 5)
- The NSAID tolmethin containing a benzylic methyl group (Figure 6)
- Sulfonamide antidiabetic drugs containing straight-chain alkyl, cycloalkyl, or aliphatic heterocycle groups attached to the terminal nitrogen of the sulfonamide group, and methyl groups attached to the benzene or alicycle or aliphatic heterocycle (Figures 8–15)
- Barbiturates mostly containing alkyl chains (Figures 16, 17)
- The anticonvulsant (antiepileptic) valproic acid (Figure 18), which contains dibutyl groups
- The following antidepressants: risperidone, which contains an azepane ring (Figure 19), and bupropion, which contains a tertiary-butyl group (Figure 20)
- The psychotropic drug Δ⁹-tetrahydrocannabinol containing an allylic methyl group (Figure 21)
- The antimuscarinic tolmethin containing a benzylic methyl group (Figure 23)
- The H1-antihistamine drugs containing a tert-butyl group: terfenadine (Figure 24) and ebastine (Figure 25)
- The H1-antihistamine hydroxyzine containing a primary alcoholic group (Figure 26)
- The natural analgesic and antipyretic drug salicin containing a hydroxymethyl group bonded to the benzene ring (Figure 27)
- The AT1 antihypertensive losartan (Figure 28) containing a hydroxy methyl group bonded to an imidazole ring
- The benzodiazepines diazepam and alprazolam, which contain a carbon (methylene group) α to carbonyl and imino moieties (Figures 30 and 31, respectively)

2.1. NSAIDS

The chemical classification of NSAIDS is given in the first part of this review series [4]. The two NSAIDS considered in this section, ibuprofen and tolmetin are of the arylalkanoic acid class.

2.1.1. Ibuprofen

Ibuprofen (Figure 5) is an arylpropionic acid NSAID used in the management of arthritis as well as for its analgesic and antipyretic properties. It acts as an NSAID by inhibiting COX and consequently PGE2, which is implicated in the inflammation process [5]. Ibuprofen is a chiral drug existing in two enantiomeric forms: S(+) and R(-). The NSAID activity of ibuprofen has been reported to reside in the S(+) enantiomer [6–8], which is now marketed in a number of countries as dexibuprofen; however, in most countries, the drug is used as the racemate. The possible reason why large pharmaceutical companies tend to market racemic equivalent ibuprofen is that the levo enantiomer is metabolically converted in vivo to the dextro enantiomer [9]. The isobutyl group in ibuprofen contains three classes of carbon: two primary (C3, C3), one tertiary (C2), and one benzylic (C1) (Figure 5). As depicted in Figure 4, phase I metabolic hydroxylation occurs at the three carbons to varying extents [9–14]. 3-Hydroxyibuprofen is further oxidized via the aldehyde intermediate to the carboxylic acid metabolite. The benzylic-carbon oxidation results in the formation of a chiral secondary alcohol (1-hydroxyibuprofen). Both the intrinsic- and the metabolically generated carboxyl groups are further metabolized in phase II to glucuronide conjugates. All the metabolites of ibuprofen are devoid of pharmacological activity [11, 14].
The role of the benzylic methyl group, since the pharmacophore
2.2. Tolmetin

Tolmetin (Figure 6) is a pyrrole acetic acid NSAID. It is metabolized by the hydroxylation of the benzylic methyl group to the active hydroxymethyl derivative, which is further oxidized to the inactive 5-carboxybenzoyl-1-methylpyrrole-2-acetic acid in the rat, monkey, and human [15, 16]. Both the intrinsic and metabolically produced carboxyl groups are further metabolized in phase II to the inactive glucuronide conjugates. The retention of COX-inhibiting activity by the hydroxymethyl metabolite may indicate an auxiliary pharmacophoric role of the benzylic methyl group, since the relatively large phenyl group is responsible for the primary pharmacophoric role.

2.2. Sulfonylurea Antidiabetics

Sulfonylurea antidiabetics have the general structure shown in Figure 7, with the framed moiety representing the pharmacophore.

In the first-generation sulfonylureas in Figure 7, R1 is a small lipophilic group such as methyl or chloro, while R2 is a lipophilic alkyl or cycloalkyl group, mostly cyclohexyl. In the second-generation sulfonylureas, the alkyl and cycloalkyl substituents at R2 are mostly maintained while the substituent
at R₁ is a large p-((β-arylcarboxamidoethyl) group (Figure6). This latter group enhances antidiabetic activity through strong binding affinity to the ATP K⁺ channel [17]. On the other hand, according to Foye (2013) [17], the small lipophilic groups at R₁ in the first-generation sulfonylureas have little influence over activity. Hence, they may have been included to play auxiliary pharmacophoric or auxophoric roles. Only methyl groups at R₁ are within the scope of this review.

The first-generation sulfonylurea oral antidiabetics surveyed in this review include acetohexamide, tolbutamide, chlorpropamide, and tolazamide, while the second-generation members include glyburide (glibenclamide), glimepiride, and glipizide [18].

Mechanistically, the sulfonylurea antidiabetics act by binding to the specific receptor for sulfonylureas on β-pancreatic cells, blocking the inflow of potassium (K⁺) through the ATP-dependent channel. The flow of K⁺ within the β-cell goes to zero; the cell membrane becomes depolarized, thus removing the electric screen, which prevents the diffusion of calcium into the cytosol. The increased flow of calcium into β-cells causes contraction in the filaments of actomyosin responsible for the exocytosis of insulin, which is therefore promptly secreted in large amounts [19].

2.2.1. Acetohexamide

Acetohexamide (Figure 8) is metabolized by (i) reduction of the carbonyl group to give a hydroxy metabolite that is 2.5 times as active as the parent drug, as well as (ii) stereoselective oxidation of the cyclohexyl ring to trans-4’-hydroxyacetohexamide, which is inactive as an oral antidiabetic [20, 21].

![Figure 8. Metabolic pathways of acetohexamide.](image)

2.2.2. Tolbutamide

Tolbutamide (Figure 9) is primarily metabolized by benzylic methyl oxidation to the primary alcoholic hydroxymethyl group, which is further oxidized to the carboxyl group (Figure 9) [22, 23]. While the hydroxymethyl metabolite is equiactive with tolbutamide, the carboxy metabolite is inactive [20, 22]. A minor route of tolbutamide metabolism occurs via butyl chain oxidation at the ω and ω-1 carbons to give primary and secondary alcohol metabolites, respectively, which have minimal antidiabetic activity (Figure 9). An inference can be made from the ratio of the hydroxy metabolites of tolbutamide: when a benzylic methyl group and an alkyl chain are present in the same drug molecule, the preference of metabolic oxidation is for the benzylic methyl group. Substantiation of the inference is given by the higher stability of the benzylic free radical involved in the oxidation of the benzylic methyl group compared to the alkyl-chain free radicals. The stability of the benzylic free radical is due to resonance stabilization by the aromatic ring, as depicted in Figure 10. The metabolic oxidation of the benzylic methyl group occurs per the mechanism of alkyl hydroxylation shown in Figure 3.
2.2.3. Chlorpropamide

Chlorpropamide (Figure 11) has been developed as a variant of tolbutamide in order to prolong the drug’s antidiabetic effect with the consequent enhancement of potency. Chlorpropamide is slowly metabolized by alkyl-chain oxidation at the \( \omega \) and \( \omega-1 \) carbons to give primary and secondary alcohols, respectively (Figure 10) [20, 24]. Both metabolites have minimal antidiabetic activity [20]. It should be noted that in chlorpropamide metabolism, the secondary alcohol (55% of dose) predominates over the primary alcohol (2%) [24] (Figure 11). A possible explanation of this finding resides in the higher stability of the intermediate secondary-propyl free radical compared to the primary-propyl free radical. In the absence of corresponding data on metabolite concentrations, the analogy could be extended to the butyl group in tolbutamide (section 1.2.2).

2.2.4. Tolazamide

Tolazamide (Figure 12) contains an azepane ring bonded to the terminal sulfnylurea nitrogen and a methyl group bonded to the aromatic ring. The metabolism of tolazamide is depicted in Figure 12. The azepane ring is oxidized at position 4’ to the 4’ hydroxy group, while the benzylic methyl group is oxidized sequentially to the hydroxymethyl and carboxyl groups [25]. It is noteworthy that the concentrations of the two alcoholic metabolites are almost equal, which leads to the inference that thebenzyl and azepinyl free radicals are almost of equal stability. However, as far as activity is concerned, the hydroxymethyl metabolite is equiactive with the parent drug, while the azepenyl alcohol metabolite is only weakly active. Furthermore, the carboxy metabolite resulting from the hydroxymethyl group oxidation is inactive.
2.2.5. Glibenclamide

Glibenclamide (also known as glyburide) (Figure 12) is a second-generation sulfonylurea oral antidiabetic. It contains a cyclohexyl group bonded to the terminal nitrogen of the sulfonylurea moiety. The cyclohexyl ring forms the main site of metabolism of the drug; it is stereoselectively hydroxylated to 3-cis and 4-trans isomers (Figure 13) with the latter isomer being the major metabolite [26, 27]. The two metabolites have little hypoglycemic effect compared to the parent drug. However, retention of 4-trans-hydroxygluburide may prolong the hypoglycemic effect of the agent in those with severe renal impairment [27].

2.2.6. Glimepiride

The cyclohexylmethyl group in glimepiride (Figure 14) allows the drug to exist incis and trans isomeric forms; the active antidiabetic form is the trans isomer. The latter is metabolized, as shown in Figure 14, through the sequential oxidation of the cyclohexylmethyl group to the hydroxymethyl and carboxy metabolites [28, 29]. The hydroxymethyl metabolite is an active antidiabetic in animal models, while the carboxyl metabolite is inactive [29].
2.2.7. Glipizide

Glipizide (Figure 15) is a second-generation sulfonylurea with R in Figure 6 as cyclohexyl substituent. It is metabolized by stereoselective hydroxylation to 4-trans and 4-cis-hydroxyglipizide [30]. No data are available on the activity of the hydroxy metabolites of glipizide.

\[ \text{Glibizide} \downarrow \text{CYP2C9} \]
\[ \text{trans-4-hydroxy glipizide} \quad + \quad \text{cis-3-hydroxy glipizide} \]

**Figure 15.** Metabolism of glipizide.

2.3. Barbiturates

Barbiturates are CNS depressants used as sedatives and hypnotics, anesthetics, and anti-seizure drugs. Barbiturates’ primary mechanism of action is inhibition of the central nervous system (CNS). The CNS depression is brought about by stimulating the inhibitory neurotransmitter system in the brain called the gamma-aminobutyric acid (GABA) system. The GABA channel is a chloride channel that has five cells at its gate. When barbiturates bind to the GABA channel, they cause the chloride ion channel to open, which allows chloride ions into the cells in the brain. The entry of the chloride ions into the brain leads to increased negative charge and alteration of the voltage across the brain cells. This change in voltage makes the brain cells resistant to nerve impulses, thus depressing them [31].

Most barbiturates contain alkyl groups of varying lengths. Being lipophilic, these alkyl groups are functionalized by metabolic hydroxylation at different positions. The primary alcohols resulting from oxidation of ω carbons are usually further metabolized to carboxylic acids. Amobarbital and pentobarbital (Figures 16 and 17, respectively) are taken as representative examples of barbiturates that contain alkyl groups. Amobarbital has ethyl and amyl groups bonded to C5 of barbituric acid, while pentobarbital has ethyl and 2-methylbutyl groups bonded to C5 of barbituric acid (Figures 16 and 17). Amobarbital is metabolized by 3'-hydroxylation to give 3'-hydroxyamobarbital as nearly the sole metabolite (Figure 16) [32–34]. On the other hand, the 2-methylbutyl group in pentobarbital undergoes ω and ω-1 metabolic oxidation to give primary- and secondary-alcohol metabolites, respectively (Figure 17) [35]. The primary alcohol metabolite of pentobarbital is further oxidized to the carboxylic acid. The three metabolites of pentobarbital (the two alcoholic metabolites and the carboxyl metabolite) are further conjugated by glucuronic acid in phase II (Figure 17) [35]. The alcoholic and the carboxylic acid metabolites of pentobarbital, and their glucuronide conjugates, are inactive as sedative-hypnotics [35]. In contrast to the alcoholic metabolites of pentobarbital, 3'-hydroxyamobarbital has not been reported to undergo glucuronide conjugation—possibly because, being a tertiary alcohol, it is sterically hindered from such a metabolic pathway. In addition to metabolism, redistribution of barbiturates has been reported to play an important role in their deactivation [36]. Redistribution of the lipophilic barbiturates from the brain to other body compartments, such as adipose tissue, will lead to a reduction of their effective concentration at the receptors in the brain, thus leading to a loss of sedative-hypnotic activity. On the other hand, amobarbital is rapidly metabolized; however, its extended activity has been attributed to the 3'-hydroxy metabolite, which is present in diminished concentration but is, nevertheless, longer acting than the parent drug [34].
peridone is considered an atypical antipsychotic drug and is used in the treatment of schizophrenia. In addition, by targeting serotonin 5HT2A and D2 receptors, risperidone decreases psychotic and aggressive behavior. By targeting serotonin 5HT2A and D2 receptors, risperidone decreases psychotic and aggressive behavior. By targeting serotonin 5HT2A and D2 receptors, risperidone decreases psychotic and aggressive behavior. By targeting serotonin 5HT2A and D2 receptors, risperidone decreases psychotic and aggressive behavior.
It is used off-label in the treatment of ADHD in children. The metabolism of risperidone is stereoselectively catalyzed (i) by CYP2D6 at the aliphatic heterocycle to give the major enantiomer (+)-9-hydroxyrisperidone, and (ii) by CYP3A4 to (-)-9-hydroxyrisperidone (Figure 18) [40–43]. Both enantiomers are equiactive with risperidone and have been developed into the racemate antipsychotic drug paliperidone [40–42]. Almo and Lopez-Mufioz (2013) [42] have reviewed the clinical use of both risperidone and paliperidone, stressing the pharmacokinetic and pharmacodynamic bases on which the metabolite drug has been developed. Further, the metabolically-formed hydroxy group in paliperidone has been esterified with palmitic acid to give paliperidone palmitate (Figure 19) is a depo-long-acting injectable prodrug formulation indicated for a single dose to be given once monthly [44]. The active drug is released in the blood by esterase hydrolysis.

Paliperidone palmitate is an example of a prodrug that has been developed from a metabolite drug; hence, it can be described as a metabolite prodrug. Other metabolite prodrugs will be presented and discussed in due course.

**Figure 19.** Metabolism and metabolite prodrug development of risperidone into paliperidone palmitate.

### 2.4.3. Bupropion

Bupropion (Figure 20) is an atypical antidepressant drug used to treat major depressive disorder (MDD) and seasonal affective disorder; it is also used off-label as a smoking cessation aid. Mechanistically, bupropion enhances both noradrenergic and dopaminergic neurotransmission via reuptake inhibition of the norepinephrine and dopamine transporters. In addition, its mechanism of action may involve the presynaptic release of norepinephrine and dopamine. The major active metabolite of bupropion is hydroxybupropion (Figure 20) [45, 46]. The groups in this metabolite are positioned in such a way as to allow for the occurrence of cyclization, thus preventing further oxidation of the hydroxymethyl group to the carboxyl group and the consequent loss of activity. The cyclic metabolite is an active antidepressant [46].

**Figure 20.** Metabolic pathways of bupropion.
2.4.4. Δ⁰-Tetrahydrocannabinol

Δ⁰-Tetrahydrocannabinol (Δ⁰-THC, Figure 21) is the psychoactive hallucinogenic constituent in Cannabis sativa (hashish and marijuana). It contains three allylic carbons at positions 11, 8, and 10a (Figure 21). The allylic positions at C11and C8 are metabolically hydroxylated, with the former hydroxylation resulting in the major equiactive hydroxymethyl metabolite; due to steric hindrance, position 10a is not hydroxylated. The C11 hydroxymethyl metabolite is further metabolically oxidized to the inactive 11-carboxy-Δ⁰-THC metabolite (Figure 21) [47, 48]. The resonance stabilization of the allyl free radical in Δ⁰-THC that accounts for the formation of the major allylic hydroxy metabolite is depicted in Figure 22.

![Figure 21. Metabolism of Δ⁰-tetrahydrocannabinol.](image)

![Figure 22. Resonance structures of the allyl free radicals in Δ⁰-THC.](image)

2.4.5. Tolterodine/Fesoterodine

Tolterodine (Figure 23) is an antimuscarinic drug used in the treatment of overactive bladder (OAB). As shown in Figure 23, tolterodine is metabolized (i) through mono-desisopropylation to give an inactive metabolite, and (ii) through benzylic-methyl group oxidation to give 5-hydroxymethyl tolterodine (5-HMT), which is equiactive with the parent drug [49–52]. Despite being equiactive to its parent drug, 5-HMT did not qualify for the status of metabolite drug because of its low log P value of 0.73 and the associated poor bioavailability [49]. However, the problem was resolved by esterifying the aromatic hydroxy (phenolic) group with isobutanoic acid to produce the prodrug fesoterodine, which has a log D<sub>7.4</sub> value of 5.7 [49] and hence enjoys a substantial improvement in bioavailability.

Fesoterodine is the second example of parent-drug equiactive metabolites to have been developed into metabolite prodrug. The first example from this class of prodrugs is paliperidone palmitate, discussed in Section 1.4.1. Further discussion of metabolite drugs and prodrugs will be given in Section 2.
2.4.6. Terfenadine/fexofenadine

Terfenadine (Figure 24) is a second generation H1-antihistamine free of the sedative side effect associated with the first-generation H1-antihistamines. Terfenadine is almost completely metabolized by benzylc-methyl-group oxidation to an equiactive carboxy metabolite, as shown in Figure 24 [33], and it is thus considered to be a prodrug. However, despite this advantage, terfenadine was withdrawn from clinical use because of its cardiotoxic effect [54]. In the interim, its carboxy metabolite, being free of cardiotoxicity, was developed into a drug of its own right under the name of fexofenadine. As shown in Figure 24, fexofenadine is amphoteric and thus is capable of existing as a zwitterion at physiologic pH [55]. The existence of fexofenadine as zwitterion at physiologic pH may be explained by the carboxylic group’s interaction with the basic pyridinyl nitrogen via folded conformers [56]. Generally, zwitterions do not cross the blood-brain barrier and hence do not cause sedation [56].

2.4.7. Ebastine/Carebastine

Ebastine (Figure 25) is a second-generation non-sedating H1-antihistamine. Its structure is similar to that of terfenadine. As in the latter drug, in ebastine the benzylc methyl group is metabolically oxidized to the carboxyl group after an intermediate step in which hydroxymethyl metabolite is formed as shown in Figure 25. The resulting metabolite, given the name carebastine, is more active than the parent drug and accounts for nearly all the H1-antihistaminic activity [57]. Despite its high log P value of 6.9 [58], ebastine does not cross the blood-brain barrier, and accordingly it does not cause sedation. On the other hand, carebastine, the active metabolite of ebastine, exists as zwitterion at physiologic pH (Figure 24) and accordingly does not cross the blood-brain barrier. Further, like terfenadine (Section 1.4.5), ebastine is cardiotoxic [59]. It is worth mentioning that, despite carebastine lack of cardiotoxicity relative to its parent drug, it has not been
developed into a drug of its own right in analogy with fexofenadine (Section 1.4.5). Almirall-Prodesfarma, a Spanish pharmaceutical company, reached stage III in the development of carebastine for the treatment of allergic conjunctivitis and allergic rhinitis, but the company subsequently discontinued the endeavor [60].

![Figure 25. Major pathway of ebastine metabolism.](image)

2.5. Metabolic Conversion of Intrinsic Hydroxymethyl Groups in Parent Drugs to Active Carboxy Metabolites

As has been shown in examples in sections 1.1 through 1.4, carboxy-metabolites can result from oxidation of hydroxymethyl groups, which are either intrinsic to the drug or form from the oxidation of ω-methyl groups in alkyl chains or methyl groups attached to cycloalkyl or aromatic rings. In all cases cited, the carboxy metabolites were found to be pharmacologically inactive: that is, they did not give the same effect as the corresponding parent drugs. However, this observation should not be generalized. Three prominent examples in which intrinsic hydroxymethyl groups are metabolically oxidized to the carboxyl groups with retention of activity are as follows: hydroxyzine to cetirizine, salicin to salicylic acid, and losartan to losartan carboxylic acid.

2.5.1. Hydroxyzine/Cetirizine

Hydroxyzine (Figure 26) is a first-generation H1-antihistamine. H1-antihistamines are generally lipophilic in nature, a property that causes them to cross the blood-brain barrier to cause sedation as a main side effect [61]. Hydroxyzine is primarily metabolized by oxidation of the primary alcoholic group to give the equiactive carboxyl metabolite (Figure 26) [62]. Being appreciably more hydrophilic than hydroxyzine and capable of existing as a zwitterion at the physiologic pH of 7.4 (Figure 26), the metabolite does not cross the blood-brain barrier and therefore does not cause sedation [56]. Because of this chemical advantage, the carboxy metabolite of hydroxyzine has been developed into a second-generation H1-antihistamine of its own right under the name of cetirizine [56, 62, 63]. The existence of cetirizine as zwitterion may be explained by analogy to fexofenadine in section 1.4.5. Hydroxyzine and cetirizine are used concurrently in clinical settings; night urticaria may be a suitable indication for the sedative hydroxyzine, while in allergic reactions demanding alertness, cetirizine is indicated [56].
2.5.2. Salicin/Salicylic Acid/Aspirin

Salicin (Figure 27) is a natural product found in the bark of the willow tree. The major turning point for salicylate medicines came in 1763, when a letter from the English chaplain Edward Stone was read at a meeting of the Royal Society. Stone’s letter described the dramatic power of the willow bark extract to cure intermittent fever, pain, and fatigue [64]. As shown in Figure 27, the metabolism of salicin to salicylic acid involves acetalic ether bridge hydrolysis (reminiscent of aromatic-alkoxy dealkylation) to a phenolic group as well as primary alcohol oxidation to the carboxyl group. The latter metabolic pathway is the subject of this section.

![Figure 26. Hydroxyzine metabolism to cetirizine.](image)

![Figure 27. Metabolic pathway of salicin.](image)

Research into willow bark extract culminated in 1899, when the German drug company, Bayer, prepared aspirin by acetylating the phenolic hydroxy group in salicylic acid, which was believed to cause gastric irritation and bleeding [65]. However, subsequent research has proven that the acetyl group in aspirin is crucial to its mode of action as a COX inhibitor in the treatment of inflammation. Through transacetylation, aspirin acetylates the alcoholic hydroxy group of the serine moiety in COX, thus inhibiting it from catalyzing prostaglandin biosynthesis [66].

In addition to being one of the most widely used anti-inflammatory, analgesic, and antipyretic drugs, aspirin is now renowned for its use as a thrombolytic agent to prevent blood clotting in patients prone to stroke-attack [67–69]. Furthermore, its preventive effect in colorectal cancer has almost been established [70, 71], and in other cancers it is now being actively researched [70, 71].

Three factors played significant roles in the design and development of aspirin: (i) nature, by providing salicin from the willow bark; (ii) metabolism, by converting salicin to salicylic acid; and (iii) medicinal chemistry, by blocking the phenolic hydroxy group of salicylic acid by acetylation. Therefore, from a developmental perspective, aspirin can be described as a natural-product-metabolite-synthetic drug, while salicin can be considered a natural prodrug.

2.5.3. Losartan/Losartan Carboxylic Acid
Losartan (Figure 28) is a selective, competitive angiotensin II receptor type (AT1) antagonist used as an antihypertensive. Through the route shown in Figure 28, the 5-hydroxymethyl group in losartan is metabolized by cytochrome P450 to the 5-carboxylic acid group through intermediate aldehyde formation [72–74]. This metabolic route accounts for 14% of losartan dose; the remainder of the drug is excreted unchanged [73, 74]. The carboxy metabolite of losartan has 10–40 times the activity of the parent drug [73, 74]. Since losartan is only partially converted into an active form, it is not considered a typical prodrug.

![Figure 28. Metabolism of losartan.](image)

According to Foye [75], the hydroxymethyl group in losartan can be replaced by other groups, such as carboxy, keto, or benzimidazole, to give active ARB drugs. Such groups interact with the AT1 receptor via either ionic, ion-dipole, or dipole-dipole bindings. The considerable increase in activity of the carboxy metabolite of losartan compared to the parent drug may be explained by the metabolite’s increased affinity to the receptor caused by the stronger ion-ion or ion-dipole binding due to the ionized carboxylate group at physiologic pH compared to the hydrogen bond binding of the hydroxyl group in the parent drug.

2.6. Metabolic Oxidation of Methylene Groups Alpha (α) to Carbonyl and Imino Groups

Generally, carbon atoms alpha to carbonyl as well as imino groups undergo metabolic oxidation via mixed function oxidases [76, 77]. Examples of drugs in which such carbons are found are diazepam and alprazolam within the benzodiazepine class, whose members are used as tranquilizers, hypnotics, or anticonvulsants. The mechanism of metabolic oxidation involves, as a first step, the formation of a resonance-stabilized free radical, as depicted in Figure 29. A hydroxyl group will then be transferred to the free radical in accordance with the mechanism of metabolic alkyl oxidation shown in Figure 3.

![Figure 29. Resonance stabilization of the benzodiazepine free radical.](image)
2.6.1. Diazepam

As shown in Figure 30, diazepam is mainly metabolized by hydroxylation at the carbon atom $\alpha$ to the carbonyl and imino groups at position 3, as well as by $N$-dealkylation [78–80]. Both metabolic routes give equiactive products with respect to the parent drug, though with modified pharmacodynamics that affect the drugs’ durations of action. Both hydroxylation at position 3 and $N$-dealkylation result in increased metabolite polarity and hence enhanced metabolite elimination. In addition, glucuronide conjugation taking place at the metabolically generated hydroxy group results in deactivation as well as fast elimination of the metabolites.

![Figure 30. Metabolic pathways of diazepam.](image)

The three diazepam metabolites are pharmacologically active, though with different durations. Both oxazepam and temazepam are further metabolized in phase II (at the 3-OH group) to the glucuronide conjugates, which are inactive.

2.6.2. Alprazolam

The triazolobenzodiazepine alprazolam (Figure 31) is metabolized (i) by hepatic microsomal oxidation at C4, which is alpha to two imino moieties, to give 4-hydroxyalprazolam, and (ii) at the allylic carbon, the methyl group, to give $\alpha$-hydroxyalprazolam (Figure 31). Both metabolites have decreased benzodiazepine receptor affinity compared to the parent drug [85].

![Figure 31. Metabolic pathways of alprazolam.](image)

3. Discussion

When studying the effect of drug molecules’ metabolic hydroxy and carboxy functionalization of alkyl groups on metabolite pharmacologic activity, several factors should first be considered. These factors include:

(a) the extent of formation of the hydroxy and carboxy metabolites
(b) the hydrophobicity of the parent drug and hydrophilicity of the metabolites
(c) the drug’s mechanism of action
(d) the favored site of metabolic hydroxylation in drug molecules containing more than one alkyl group
(e) the molecular size increase and steric effect resulting from the replacement of the small hydrogen atom in the alkyl group in the drug molecule by the larger and bulkier hydroxyl or carboxyl group in the metabolite molecule
(f) the creation of new metabolite-receptor binding mechanisms, e.g. hydrogen bonding, ion-pairing, and ion-dipole, in contrast to van der Waal’s binding of the alkyl groups

Generally, the extent of the metabolic oxidation of carbon atoms in drug molecules’ alkyl chains depends in part on the class of the carbon atom, which in turn dictates the stability of the resulting free radicals: benzylic, allylic>tertiary >secondary >primary >methyl. On the other hand, the hydrophilicity of an alcoholic hydroxyl group is determined by the strength of the intermolecular hydrogen bonds it forms. Due to steric effects, the strength of hydrogen bonding in the different classes of alcohols follows this sequence: primary > secondary > tertiary [86]. The order of the hydrophilicity of primary, secondary and tertiary alcohols follows the same sequence.

From the aliphatic hydroxy and carboxy metabolites of the cases surveyed in this review, we observe three effects on the pharmacologic activity of the metabolites relevant to their parent drugs: loss, attenuation, or retention.

3.1. NSAIDS

Loss of pharmacologic activity has been observed for ibuprofen upon metabolic hydroxylation of the isobutyl group at C1, C2 and C3 (Figure 5). In analogy with the O-demethylation of the methoxy-group-containing NSAIDS discussed in the first part of this review series [4], both pharmacodynamic and pharmacokinetic effects may account for the ibuprofen isobutyl-hydroxy metabolites’ loss of pharmacologic activity. The SAR of ibuprofen dictates that the branched isobutyl moiety is essential for optimum COX-inhibitory effect; in this context, n-butyl substitution has led to significant loss of activity [87]. This finding should imply that each of the methyl groups in the isobutyl moiety occupies a small hydrophobic pocket in COX, enabling a pharmacophoric effect that is essential for optimum activity. The hydroxy and carboxy groups in metabolite III and metabolite IV, respectively (Figure 5), are detrimental to the hydrophobic binding of the isobutyl group, and accordingly, they precipitate a loss of COX-inhibiting activity. Further, by replacing a hydrogen atom in the isobutyl group in ibuprofen, the bulkier hydroxyl or carboxyl groups in the metabolites will impart molecular-size increase and steric effects—factors that are detrimental to optimum binding between isobutyl group and COX. In addition, being hydrophilic, the hydroxyl or carboxyl group will increase the water solubility of the metabolites, hence leading to their elimination and termination of their action. Furthermore, glucuronide conjugation of the hydroxyl and carboxyl groups will considerably enhance the prospects of metabolite elimination and activity termination through substantially increasing aqueous solubility.

3.2. Sulfonylurea Antidiabetics

For the sake of discussing the effect of metabolic oxidation of alkyl and aliphatic cyclic groups in the sulfonylurea antidiabetics, we dissect the general structure of these agents, as depicted in Figure 7. To reiterate, in the first-generation sulfonylureas (Section 1.2), R1 (Figure 7) is a small lipophilic group, such as methyl or chloro, while R2 is an alkyl or aliphatic cyclic group. According to Foye (2013) [17], the R1 groups do little to increase the binding efficiency of the pharmacophore to the ATP-sensitive K⁺ channel. As such, R1 groups may be playing weak auxiliary pharmacophoric and/or auxophoric roles. On the other hand, the R2 groups in both first- and second-generation sulfonylurea antidiabetics have the auxophoric role of optimizing the pKa of the sulfonylurea group to ~5. At this
pKa value, a sulfonylurea anion is formed that is essential for interaction with the pancreatic β-cell subtypes (SUR1, SURA1, and SUR2A) through ion-ion and ion-dipole bindings [92]. Generally, metabolic change at auxiliary pharmacophores or auxophores is associated with retention of pharmacologic activity [4]. However, a discrepancy is observed for some members of the first-generation sulfonylurea antidiabetics in this respect. For instance, while the aliphatic-ring hydroxy metabolite of tolazamide (Figure 12) is active with a prolonged duration of action, the counterpart metabolite of acetohexamide (Figure 8) is inactive.

The lipophilic methyl group at R1 in the general structure of sulfonylureas (Figure 7) is metabolized by oxidation, via hydroxymethyl formation, to the carboxyl group with loss of activity in both tolbutamide and tolazamide (Figures 9 and 12, respectively). Generally, the loss of activity caused by metabolically formed carboxyl groups can be explained by two effects. Firstly, the carboxyl group is ionized at the physiologic pH of 7.4. Secondly, the carboxyl group is, in most cases, glucuronide conjugated in phase II. These two effects will result in a substantial increase of water solubility and elimination of the metabolite with the consequent loss of activity due to reduced effective concentration of the metabolite at the receptor. It is noteworthy that the metabolic functionalization of the lipophilic benzylc methyl group to the carboxyl group in tolbutamide (Figure 8), with the consequent enhanced elimination and loss of activity, has led to the development of chlorpropamide (Figure 10). By employing bioisosterism, medicinal chemists replaced the benzylc methyl group in tolbutamide with a chloro group, which is not prone to metabolism, to obtain chlorpropamide. Due to this manipulation of metabolic stability, chlorpropamide can be used at a lower dose and frequency than tolbutamide.

In the second-generation sulfonylurea antidiabetics, the small lipophilic groups of the first generation at R1 (Figure 7) have been replaced by the larger p-(β-arylcarboxyamidoethyl) group, such as in glimepiride (Figure 14), in order to attain strong binding affinity to the ATP-sensitive K+ channel [17]. Metabolism of this group is not within the scope of this review.

3.3. Barbiturates

The metabolic oxidative hydroxylation of alkyl chains in barbiturates has resulted in variable levels of activity subject to the class of the resulting alcohol. In pentobarbital (Figure 17), the primary and secondary alcohols, respectively resulting from ω and ω-1 oxidation, are sufficiently hydrophilic to jeopardize the hydrophobicity requirement for blood-brain barrier crossing [89]. In addition to hydrophilicity, the factors of increased steric effect, molecular size, and surface area may come into play to hinder the hydroxy metabolite from fitting in the receptor, thus leading to either attenuation or loss of activity as governed by the extent of each factor. On the other hand, in amobarbital (Figure 16), metabolic oxidation occurs mainly at the ω-1 tertiary carbon, resulting in a tertiary alcohol, 3'-hydroxyamobarbital. Despite being less active, 3'-hydroxyamobarbital has been reported to be responsible for the sedative-hypnotic activity of amobarbital [34]. With reduced hydrogen bonding ability, and the consequent diminishment of hydrophilicity, due to steric effects in alcohols, 3'-hydroxyamobarbital will cross the blood-brain barrier in sufficient concentration to produce sedative-hypnotic effects.

The loss of activity of carboxy metabolites of barbiturates may be explained similarly to the NSAIDS (Section 3.1).

3.4. Accounting for the Activity of the H1-Antihistamines’ Carboxy Metabolites: Hydroxyzine, Terfenadine, and Ebastine

Methyl groups that are bonded to aromatic or cycloalkyl rings, or terminal in alkyl chains (i.e. ω methyls) in drug molecules are usually oxidized to inactive carboxy metabolites through the formation of mostly active hydroxymethyl intermediates. The loss of pharmacologic activity indicates that the methyl groups in such cases play pharmacophoric roles, at least of an auxiliary nature. However, when the methyl or hydroxymethyl group is distant from a predetermined pharmacophore, the situation is different: metabolic oxidation of either group to the carboxyl group does not cause loss of activity of the resulting metabolite. This has been the case with the three H1-
antihistamines hydroxyzine, terfenadine, and ebastine, which are respectively metabolized to equiactive cetirizine (Figure 26), fexofenadine (Figure 24), and carebastine (Figure 25).

Hydroxyzine is a first generation H1-antihistamine. With a log P value of 3.5 [90], it is hydrophobic enough to cross the blood-brain barrier, interacting with cholinergic, serotonergic, and adrenergic receptors and causing sedation [91]. On the other hand, cetirizine, the carboxy-metabolite drug of hydroxyzine, has a log P value of 1.5[92] and exists as zwitterion at physiologic pH of 7.4. Due to these properties, cetirizine does not cross the blood-brain barrier and does not accordingly cause sedation. As shown in Figure 26, in both hydroxyzine and cetirizine, the metabolically exchanged groups are distant from the pharmacophore, and accordingly, the two drugs are therapeutically equiactive as H1-antihistamines. The ethoxyethanol group in hydroxyzine and the ethoxyacetic acid group in cetirizine each also play an auxophoric role. A similar situation can be observed for the terfenadine/fexofenadine H1-antihistamine pair (Figure 25). However, here, the carboxyl group in fexofenadine plays a pharmacodynamic rather that a pharmacokinetic role. Terfenadine causes heart arrhythmias by blocking the hERG channel K+ current [93]. On the other hand, the ionized carboxylate group (COO-) in fexofenadine reduces this blockage by over three orders of magnitude, thus rendering this drug free of the cardiotoxic effect [94].

The inference that can be made from the two H1-antihistamine pairs presented above is that when metabolic changes occur at groups distant from the pharmacophores, the original pharmacologic activity will not be affected. Further, beneficial pharmacokinetic and/or pharmacodynamic modifications may result in the metabolites’ warranting development into fully-fledged drugs. An extended definition of auxiliary pharmacophores is given in Section 2.5.7.

3.5. Aspirin Is an NSAID of Its Own Disposition

In salicin (Figure 27), the acetalic group is metabolically converted to a hydroxyl group in a reaction reminiscent of O-dealkylation, while the hydroxymethyl group is oxidized to the carboxyl group to give salicylic acid. The phenolic hydroxyl group in salicylic acid was suspected to be the cause of stomach irritation and bleeding, and it was hence esterified by acetic anhydride to give aspirin. However, later, it was proven [95-97] that the gastrointestinal adverse effects of aspirin were associated with the inhibition of COX1 and accordingly the inhibition of PGE1 formation, i.e., synthesis of the prostaglandin involved in the protection of gastric mucosa against acid attack. Sometime then elapsed before the mechanism of the anti-inflammatory activity of aspirin was understood to be caused by acetylation of the serine moiety in COX [98]. That being the case, the benzene ring and the carboxyl group in aspirin are likely playing auxiliary pharmacophoric roles by properly anchoring the aspirin molecule in the COX-active cavity, thus facilitating the transfer of the acetyl group to the serine moiety.

3.6. Subtexts Arising from Hydroxy and Carboxy Metabolic Functionalization of Alkyl Moieties in Drug Molecules

The aim of this section is to provide focused information on some general and specific issues that have been extracted from the individual cases of alkyl-moiety metabolic hydroxy functionalization. The information presented and discussed includes definitions, significance, implications and/or applications of the selected issues, which include:

- Metabolism of methyl groups in drug molecules
- Metabolic hydroxylation of alicycles and aliphatic heterocycles in drug molecules
- Inferences from hydroxymethyl group in drug metabolites regarding origin and significance
- Development of metabolite drugs and prodrugs from metabolites equiactive with parent drugs
- Activity of carboxy metabolites
- Significance of the carboxy metabolite of Δ⁹-tetrahydrocannabinol
- Primary and auxiliary pharmacophoric properties
3.6.1. Metabolism of Methyl Groups in Drug Molecules

Methyl groups assume their importance in drug molecules due to their small size, higher steric effect with respect to the hydrogen atom, hydrophobicity, isosterism with a number of groups, and historical inclusion in drug molecules. They are found in drug molecules at ω-carbons in both straight- and branched-chain alkys, as substituents in aromatic (benzene) rings and alicycles, and as substituents in secondary and tertiary amino moieties. In branched-chain alkys, methyl groups are found as isopropyl, isobutyl, or tert-butyl moieties. In all of these forms, the methyl group is metabolically oxidized by CYP450 enzymes to the hydroxymethyl group. The sequential oxidation of the latter group to the carboxylic acid follows in most cases. When there is more than one equivalent methyl group in a drug molecule, only one group will be metabolically oxidized.

3.6.2. Metabolic Hydroxylation of Alicycles and Aliphatic Heterocycles in Drug Molecules

Six-membered alicycle (cyclohexyl) and heterocycle (piperidinyl) groups are often encountered in drug molecules of various pharmacologic classes. For the most part, rings are stereoselectively metabolized by hydroxylation at the positions 3 and 4, which are less sterically hindered, compared to other positions (in the ring), to form cis and trans isomers. Pharmacologic action may also be a function of stereoselective metabolism. For instance, the oral antidiabetic acetohexamide is mainly metabolized to trans-4'-hydroxyacetohexamide, which is inactive. The cyclohexyl ring in glibenclamide is metabolically oxidized to 3-cis and 4-trans-hydroxy metabolites with a substantial attenuation of antidiabetic activity. A similar effect has been observed for tolazamide, in which the azepane ring is metabolically hydroxylated at position 4 (Figure 11) with a substantial loss of activity. Achieving the optimum activity level of sulfonylureas demands that the R substituent in the general structure (Figure 7) be lipophilic with 3 to 6 carbons, whether open chain or cyclic [99]. Metabolic hydroxylation of this group will compromise the absolute lipophilic requirement, leading to either attenuation or loss of antidiabetic activity.

An interesting case of metabolic hydroxylation of alicycles and aliphatic heterocycles is given by the psychotropic drug phencyclidine, which contains both cyclohexyl and piperidinyl groups. Phencyclidine is mainly metabolized by hydroxylation at position 4 of the cyclohexyl ring to the active cis- and trans-4-phenyl-4-(1-piperidinyl)cyclohexanol (Figure 32) [100]. In addition, the piperidinyl ring in phencyclidine is metabolically hydroxylated to a minor extent at position 4 to give 4-phenyl-4-(1-cyclohexyl)piperidinyl alcohol [101]. The pharmacologic activity of the piperidinyl-hydroxy metabolite of phencyclidine has not been reported. A tentative inference can be made heeding the phencyclidine-metabolic hydroxylation example: when an alicycle and aliphatic heterocycle are parts of the same molecule, metabolic hydroxylation favors the alicycle.

![Figure 32. Metabolism of phencyclidine.](image)

3.6.3. Inferences from Hydroxymethyl Metabolites

Hydroxymethyl groups (-CH₂OH), either intrinsic to drug molecules or metabolically formed, play pharmacophoric and/or auxophoric roles. Here, we highlight the significance of the hydroxymethyl group as derived from the relevant cases in Section 1.
(a) Hydroxymethyl groups may be intrinsic to drug molecules, or they may result from the metabolic oxidation of methyl groups bonded to aromatic or alicyclic rings (or terminal methyl groups) in alkyl chains—i.e., ω carbons.

(b) Intrinsic- or metabolically formed hydroxymethyl groups are almost invariably metabolically oxidized to carboxyl groups.

(c) The hydroxymethyl metabolites are almost invariably equiactive with the parent drugs, whereas the carboxy metabolites (resulting from the sequential oxidation of the hydroxymethyl metabolites) are mostly inactive (with only a few exceptions being equiactive with the parent drug). These exceptional cases are those in which the hydroxymethyl groups are distant from the primary pharmacophore.

(d) Hydroxymethyl metabolites’ invariable retention of pharmacologic activity resulting from methyl-group oxidation probably reflects the auxiliary pharmacophoric status of the methyl group in the parent drug.

(e) Of the hydroxymethyl metabolites that are equiactive with their parent drugs, only that of tolterodine has been developed into a prodrug of its own right; this drug carries the name of fesoterodine (Figure 22).

3.6.4. Development of Metabolite Drugs and Prodrugs from Parent-Drug Equiactive Metabolites

The metabolite drugs presented in section 1 include the H1-antihistamines cetirizine (Figure 25) and fexofenadine (Figure 23), the carboxy metabolites of hydroxyzine and terfenadine, respectively. Both drugs are more hydrophilic than their respective parent drugs and are capable of existing as zwitterions at physiologic pH. Due to these properties, the two drugs do not cross the blood-brain barrier, and accordingly, they do not cause sedation. In addition, the carboxyl group in fexofenadine seems to offer an ionic binding site that is responsible for the removal of cardiotoxic adverse effects from the parent drug terfenadine. The advantages of both cetirizine and fexofenadine that warranted their development into metabolite drugs may be described as intrinsic. However, cases are known in which these advantages are artificially produced, such as in metabolite prodrugs. In such cases, the metabolite is equiactive with the parent drug, but due to high hydrophilicity, it suffers the disadvantages of low bioavailability and short duration of action. Chemists have responded to this situation by producing ester prodrugs. The two metabolite prodrugs presented in Section 1 are the antipsychotic paliperidone palmitate (Figure 18) and the antimuscarinic fesoterodine (Figure 22). The preparation of ester prodrugs of hydroxy metabolites equiactive with the parent drugs to attain improved pharmacokinetic properties may be extended to other cases if sufficiently warranted.

3.6.5. Activity of Carboxy Metabolites

In most of the surveyed drugs in Section 2, where terminal methyls in alkyl chains (ω-carbons), benzylic methyls, and methyls directly bonded to alicycles are metabolically oxidized to the carboxy group, a loss of pharmacologic activity due to the parent drug has been observed. However, two cases, terfenadine and ebastine, are unique in that the oxidation of the benzylic methyl group has resulted in retention of pharmacologic activity. In these two particular cases, the metabolic oxidation of the methyl group to the carboxyl group has taken place at a position distant from the primary pharmacophore (Figures 24 and 25). Of all the metabolically generated polar functional groups in drug molecules, the carboxyl group stands alone in that it is almost completely ionized at the physiologic pH of 7.4. If such metabolic change occurs at a pharmacophoric site, the new state of ion-pairing interactions replacing the van der Waals interaction of the methyl group will tend to change
the pharmacodynamics of the parent drug, leading to a loss of activity. On the other hand, the ionized carboxyl group introduces a pharmacokinetic dimension—which substantially enhances the polarity, water solubility, and elimination of the metabolite as per se or as the glucuronide conjugate, thus causing a significant reduction of the metabolite’s effective concentration at the receptor. It is noteworthy that when a carboxyl group is involved in zwitterion formation with an aliphatic amino group, such as in cetirizine, fexofenadine, and carebastine, that group will not be subject to glucuronide conjugation. In fact, glucuronide conjugation has not been reported as a metabolic route for any of the three aforementioned drugs.

3.6.6. Significance of the Carboxy Metabolite of Δ⁹-Tetrahydrocannabinol (Figure 20)

Δ⁹-Tetrahydrocannabinol is the major psychoactive constituent of *Cannabis sativa*. The use of *Cannabis* products, hashish and marijuana, is illegal in many countries and is punishable by law. The detection of cannabis-product use is based on urinalysis of the constituent metabolites. For this purpose, presumptive immunoassays have been developed based on the carboxy metabolite of Δ⁹-tetrahydrocannabinol, i.e., carboxy-Δ⁹-tetrahydrocannabinol (Figure 21). Confirmation tests of the presence of this metabolite are carried out by chromatography-mass spectrometry methods such as GC-MS after trimethylsilyl derivatization or LC-MS [102, 103].

3.6.7. Primary and Auxiliary Pharmacophores

In the first part of this review series [4], we classified the pharmacophore as primary and auxiliary based on the “message/address” concept suggested by Dr. Portoghese [104]. The case of fexofenadine development as a metabolite drug of terfenadine (Figure 24) due to the cardiotoxicity of the latter has prompted us to extend the definition of an auxiliary pharmacophore. An auxiliary pharmacophore is a group that may play one of two roles: (a) properly anchoring the primary pharmacophore in the active site of the receptor, or (b) interacting with a site other than the primary site (i.e., an auxiliary site) to produce or override an adverse effect or to account for an off-label use of the drug. The cardiotoxic effect of terfenadine may be explained by the interaction of the three benzylic methyl groups with an auxiliary receptor via van der Waals binding. In fexofenadine, one of the benzylic methyl groups (in terfenadine) has been metabolically oxidized to a carboxyl group, which interacts with the auxiliary site via ionic binding. Due to its higher strength, ionic binding strongly predominates over van der Waals binding and thus dictates the nature of the pharmacologic activity of drugs in which it occurs.

4. Conclusion

The occurrence and extent of alkyl moiety hydroxy functionalization in drug molecules is predictable based on the feasibility of intermediate free radicals’ formation and stability. On the other hand, the pharmacologic activities of the alkyl moieties-hydroxy and carboxy metabolites may be predicted based on analogy with the reviewed cases. All hydroxymethyl metabolites are pharmacologically equiactive with their parent drugs while most carboxy metabolites are inactive. The development of metabolite ester prodrugs has an extendable potential when the equiactive hydroxy metabolite is characterized by poor bioavailability and/or short duration of action. The pharmacologic activities of the hydroxy and carboxy metabolites resulting respectively from alkyl or hydroxymethyl moiety functionalization are explicable on pharmacodynamic and/or pharmacokinetic grounds. In some cases, metabolic hydroxy and carboxy functionalization of alkyl or hydroxymethyl moieties has enabled distinctions to be made between primary pharmacophores, auxiliary pharmacophores, and auxophores.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. de Montellano P.R.O. Hydrocarbon Hydroxylation by Cytochrome P450 Enzymes. Chem Rev 2010, 110, 932

2. Reilly C.A.; Yost G.S. Structural and Enzymatic Parameters That Determine Alkyl Dehydrogenation/Hydroxylation of Capsaicinoids by Cytochrome P450 Enzymes. Drug Metab. Dispos 2005, 33, 530-536

3. Williams D.A. Drug Metabolism. In Foye’s Principles of Medicinal Chemistry, 7th ed.; Lemke T.; Williams D.A.; Roche V.F.; Zito S.W. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2013; p. 126. ISBN 978-1-60913-345-0.

4. El-Haj B.M.; Ahmed S.B.; Garawi M.A.; Ali H.S. Linking Aromatic Hydroxy Metabolic Functionalization of Drug Molecules to Structure and Pharmacologic Activity. Molecules 2018; 23: 2119 doi:10.3390/molecules23092119

5. Bushra R.; Aslam N. An Overview of Clinical Pharmacology of Ibuprofen. Oman Med J 2010, 25, 155-166

6. Evans A.M. Comparative Pharmacology of S-(+)-Ibuprofen and (RS)-Ibuprofen. Clinical Rheumatology 2001, 20, 9-14

7. Stock K.P.; Geisslinger G.; Loew D.; Beck W.S.; Bach G.L.; Brune K. S-Ibuprofen versus ibuprofen-racemate. Rheumatology International 1991, 11, 199-202

8. Davies N.M. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998, 34, 101-154

9. Geisslinger G.; Schuster O.; Stock K.P.; Loew D.; Bach G.L.; Brune K. Pharmacokinetics of s dextro and r levo ibuprofen in volunteers and first clinical experience of s dextro ibuprofen in rheumatoid arthritis. Eur J Clin Pharmacol 1990, 38, 493-498

10. Rudy A.C.; Knight P.M.; Brater D.C.; Hall S.D. Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. J. Pharmacol. Exp. Ther 1991, 259, 1133-1139

11. Mazaleuskaya L.; Theken K.N.; Gong L.; Thorn C.F.; FitzGerald G.A.; Altman R.B.; Klein T.E. PharmGKB summary: ibuprofen pathways. Pharmacogenetics and Genomics 2015, 25, 96-106

12. Kasprzyk-Horder B. Pharmacologically active compounds in the environment and their chirality. Chem Soc Rev 2010, 39, 4466-4503

13. Kepp D.R.; Sidelmann U.G.; Tjørnelund J. Hansen S.H. Simultaneous quantitative determination of the major phase I and II metabolites of ibuprofen in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatog B Biomed Sci Appl 1997, 696, 235-241

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 March 2020
Peer-reviewed version available at Molecules 2020, 25, 1937; doi:10.3390/molecules25081937
14. North E.J. Drugs Used to Treat Pain: Peripherally Acting Agents. In Foye’s Principles of Medicinal Chemistry, 8th ed. Roche V.F.; Zito S.W.; Lemke T.L.; Williams D.A. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2020; p. 573. ISBN 13: 978-1-4963-8502-4.

15. Summer D.D.; Dayton P.G.; Cucinell S.A.; Plostones J. Metabolism of tolmetin in rat, monkey, and man. Drug Metab Dispos 1975, 3, 283-286

16. Inactive Tolmetin metabolites: https://www.drugbank.ca/drugs/DB00500 (URL accessed on 17/02/2019)

17. Zito S.W. Drugs Used to Treat Diabetic Disorders. In Foye’s Principles of Medicinal Chemistry, 8th ed.; Roche V.F.; Zito, S.W.; Lemke T.L.; Williams D.A. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2020; p. 804-805. ISBN 13: 978-1-4963-8502-4.

18. Kharbanda C.; Alam S.M. Evolution of Sulfonylureas in the Treatment of Diabetes Mellitus. Chemistry & Biology Interface 2013, 3, 230-252

19. Ashcroft F.M. Mechanisms of the glycemic effects of sulfonylureas. Horm Metab Res 1996, 28, 456-63

20. McMahon R.E.; Marshall F.J.; Culp H.W. The nature of the metabolites of acetohexamide in the rat and in the human. J Pharmacol Exptl Therap 1965, 149, 272-279

21. Galloway J.A.; McMahon R.E.; Culp H.W.; Marshall F.J.; Young E.C. Metabolism, Blood Levels and Rate of Excretion of Acetohexamide in Human Subjects. Diabetes 1967, 16, 118-127.

22. Thomas R.C.; Ikeda G.J. The Metabolic Fate of Tolbutamide in Man and in the Rat. J Med Chem 1966, 9, 507-10

23. Tolbutamide: https://www.drugbank.ca/drugs/DB01124 (URL accessed on 16/02/2019)

24. Skillman S.G. Chlorpropamide metabolism. Am J Med 1981, 71, 1050

25. Thomas R.C.; Duchamp D.J.; Judy R.W.; Ikeda G.J. Metabolic fate of tolazamide in man and in the rat. J Med Chem 1978, 21, 725-32

26. Glyburide: https://www.drugbank.ca/drugs/DB01016 (URL accessed on 16/02/2019)

27. Peart G.F.; Boutagy J.; Shenfield G.M. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clin Pharmacol Ther 1989, 45, 277-84

28. Glimepiride: https://www.pharmgkb.org/chemical/PA449761/overview (URL accessed on 17/01/2020)
29. Glimepiride: https://www.drugbank.ca/drugs/DB00222 (URL accessed on 20/02/2019)

30. Wensing G. Glipizide: An oral hypoglycemic drug. Am J Med Sci 1989, 298, 69–71

31. Löscher W.; Rogawski M.A. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia 2012, 53, 12-25

32. Kamm J.J.; Van Loon E.J. Amobarbital Metabolism in Man: A Gas Chromatographic Method for the Estimation of Hydroxyamobarbital in Human Urine. Clin Chem 1966, 12, 789-796

33. Mehta S. Phase I Metabolism-Oxidative Reactions-Oxidation of Aliphatic and Alicyclic Compounds. Medicinal Chemistry Notes, Pharmacology, Pharmaxchange September 07, 2014, https://pharmaxchange.info/2014/09/phase-i-metabolism-oxidative-reactions-oxidation-of-aliphatic-and-alicyclic-compounds/ (URL accessed on 28/02/2019)

34. Lowry W.T.; Garriott J.C. Controlled and Non-controlled but Commonly Abused Drugs, In: Forensic Toxicology of Controlled Substances and Dangerous Drug, Plenum Press, New York, N.Y., USA, 1979; ISBN-13: 978-1-4684-3446-0

35. Moniri N.H. Drugs Used to Induce/Support Sedation and Anesthesia. In Foye’s Principles of Medicinal Chemistry, 8th ed.; Roche V.F.; Zito, S.W.; Lemke T.L.; Williams D.A. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2020; p. 429. ISBN 13: 978-1-4963-8502-4.

36. ibid

37. Valproic acid pathway, pharmacodynamics. PHARMGKB: https://www.pharmgkb.org/pathway/PA165959313 (URL accessed on 28/02/2019)

38. Loscher W. Anticonvulsant activity of metabolites of valproic acid. Arch Int Pharmacody. Ther 1981, 249, 158-63

39. Bello-Ramirez A.M.; Carreon B.Y.; Nara-Ocampo A.A. Do Structural Properties Explain the Anticonvulsant Activity of Valproate Metabolites? A QSAR Analysis. Epilepsia 2002, 43, 475-481

40. Canal C.E.; Booth R.G.; Williams D.A. Drugs Used to Treat Mental, Behavioral and Cognitive Disorders. In Foye’s Principles of Medicinal Chemistry, 8th ed.; Roche V.F.; Zito, S.W.; Lemke T.L.; Williams D.A. Editors.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2020; p. 330. ISBN 13: 978-1-4963-8502-4.

41. De Leon J.; Wynn G.; Sandson N.B. The Pharmacokinetics of Paliperidone versus Risperidone. Psychosomatics 2010, 61, 80-88
42. Alamo C.; Lopez-Mufioz F. The Pharmacological Role and Clinical Applications of Antipsychotics' Active Metabolites: Paliperidone versus Risperidone. Clin Exptl Pharmacol 2013, 3, 117-128

43. Yasui-Furukori N.; Hidestrand M.; Spina E.; Facciolá G.; Scordo M.G.; Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001, 10, 1263-8

44. Sedky K. Paliperidone palmitate: Once-monthly treatment option for schizophrenia. Current Psychiatry 2010; 9: 48-49

45. Skarydova L.; Tomanova R.; Havlikova L.; Stambergova H.; Solich P.; Wsol V. Deeper insight into the reducing biotransformation of bupropion in the human liver. Drug Metab Pharmacokinet 2014, 29, 177-84

46. Masters A.R.; Gufford B.T.; Lu Jessica B.; Metzger I.F.; Jones D.R.; Desta Z. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. J Pharmacol Exp Ther 2016, 358, 230-8

47. Sharma P.; Murthy P.; Srinivas M.M. Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications. Iran J Psychiatry 2012, 7, 140-156

48. Mechoulam R.C.; Hanus L.O.; Pertwee R.; Howlett A.C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience 2014, 5, 757-764

49. Malhorta B.; Gandelman K.; Sachse R.; Wood N.; Michel M.C. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009, 6, 4481-9.

50. Simona H.; Malhotra B. The pharmacokinetic profile of fesoterodine: Similarities and differences to tolterodine. Swiss Med Weekly 2009, 139, 146-151

51. Malhorta B.; Guan Z.; Wood N.; Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008, 45, 556-63

52. Postlind H.I.; Danielson A, Lindgren A.; Andersson S.H. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab. Despos 1998, 26, 289-93

53. Fifer E.K. Drugs Used to Treat Allergic Disorders. In Foye’s Principles of Medicinal Chemistry, 8th ed.; Roche V.F.; Zito, S.W.; Lemke T.L.; Williams D.A. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2020; p. 1015-1016. ISBN 978-1-60913-345-01058-1059 metabolism

54. Delgado L.F.; Pferferman A.; Sole D.; Naspitz C.K. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allergy Asthma Immunol 1998, 80, 333-7
55. Simons H.; Simons K.J. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011, 128, 1139-1150

56. Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008, 21, 2173–91

57. del Cuvillo A.1.; Mullol J.; Bartra J.; Dávila I.; Jáuregui I.; Montoro J.; Sastre J.; Valero A.L. Comparative pharmacology of the H1 antihistamines. J. Investig. Allergol. Clin Immunol 2006, 16, 3-12

58. Khojasteh S.C.; Wong H.; Hop C.E.C.A. In Drug Metabolism and Pharmacokinetics Quick Guide. Springer, New York, USA, 2011, p 171; ISBN 978-1-4419-5628-6

59. Hey J.A.1.; del Prado M.; Sherwood J.; Kreutner W.; Egan R.W. Comparative analysis of the cardiotoxicity proclivities of second-generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 1996, 46, 153-8

60. Carebastine (LAS X 113). https://adisinsight.springer.com/drugs/800003600 (URL accessed on 15/01/2019)

61. Nelson WL. Antihistamines and Related Antiallergic and Antiulcer Agents. In Foye’s Principles of Medicinal Chemistry, 7th ed.; Lemke T.; Williams D.A., Roche V.F.; Zito S.W. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2013; p. 1053. ISBN 978-1-60913-345-0.
62. ibid, p. 1060

63. Curran M, Scott IJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs 2004, 64, 523–561

64. Stone E. Salixalba: An Account of the Success of the Bark of the Willow in the Cure of Agues. Philosophical Transactions of the Royal Society of London 1763, 53

65. Mahdi J.G. Medicinal potential of willow: A chemical perspective of aspirin discovery. J Saudi Chem Soc 2010, 14, 317-22

66. Lei J.; Zhou Y, Xie D, Zhang Y. Mechanistic Insights into a Classic Wonder Drug—Aspirin. J Am Chem Soc 2015; 137: 70-73

67. Patrono C, Baigent C.; Hirsh J. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 33, 199S-233S

68. Patrono D.G. Platelet activation and artherothrombosis. N Engl J Med 2007, 357, 2482-2494

69. Coccheri S. Antiplatelet drugs: do we need more options? Drugs 2010, 70, 887-908
70. Aspirin and Cancer Prevention: What the Research Really Shows: https://www.cancer.org/latest-news/aspirin-and-cancer-prevention-what-the-research-really-shows.html (URL accessed on 07/03/2019)

71. Aspirin to reduce cancer risk: https://www.cancer.gov/about-cancer/causes-prevention/research/aspirin-cancer-risk (URL accessed on 07/03/2019)

72. Harrold M. Agents Affecting the Renin-Angiotensin Pathway and Calcium Blockers. In Foye’s Principles of Medicinal Chemistry, 7th ed.; Lemke T.L.; Williams D.A.; Roche V.F.; Zito S.W. Eds.; Wolters Kluwer and Lippincott Williams and Wilkins: London, UK, 2013; p. 763. ISBN 978-1-60913-345-0

73. Stearns R.A.; Chakravatry P.K.; Chen R.; Chin S.H. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995, 23, 207-215

74. Iwamura A.; Fukami T. Nakaajima M.; Yokoi T. CYP2C9 mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab Dispos 2011, 39, 838-846

75. Reference 72, p. 763

76. Altahir S.L. Phase I reactions Oxidative Reactions. https://slideplayer.com/slide/14180376/ (URL accessed on 19/01/2019)

77. Gante K.M.F. Metabolic Changes of Drugs and Related Organic Compounds. https://www.scribd.com/presentation/215273318/3-Metabolism (URL accessed on 19/01/2019)

78. Perucca E.; Gatti G.; Cipolla G.; Spina E.; Barel S.; Soback S.; Gips M.; Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994, 56, 471-476.

79. Greenblatt D.J.; Woo E.; Allen M.D.; Orsulak P.J.; Shader R.I. Rapid recovery from massive diazepam overdoses. J. Am. Med. Assoc 1978, 420, 1872-1874.

80. Benzodiazepine Pathway, Pharmacokinetics. https://www.pharmgkb.org/pathway/PA165111375 (URL accessed on 21/01/2019)

81. Vree T.B.; Baars A.M.; Wuis E.W. HPLC analysis and pharmacokinetics of the enantiomers of R,S-oxazepam and R,S-temazepam with their corresponding glucuronide conjugates in urine and plasma of man. Acta Neuropsychiatr 1990, 2, 95-100.

82. Vree T.B.; Baars A.M.; Wuis E.W. Direct high-pressure liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates. Pharmaceutisch Weekblad 1991, 13, 83–90
83. Liu J.; Stewart J.T. Simultaneous Separation of Diazepam and Its Chiral and Achiral Metabolites by HPLC on a Chiralcel OD-R Column. J Anal Letters 1997, 30, 1555-1566.

84. Pham-Huy C.; Villain-Pautet G.; Hua H.; Chikhi-Chorfi N.; Galons H.; Thevenin M. Separation of oxazepam, lorazepam, and temazepam enantiomers by HPLC on a derivatized cyclodextrin-bonded phase: Application to the determination of oxazepam in plasma. J Biochem Biophys Methods 2003, 54, 287-9

85. Greenblatt D.J.; von Moltke L.L.; Harmatz J.S.; Ciraulo D.A.; Shader R.I. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. 1993, 54 Suppl: 4-11: discussion 12-4

86. Chandra A.K.; Sannigrahi A.B. Hydrogen-Bonding Properties of Alcohols. J. Phys. Chem 1965, 69, 2494–2499

87. DeRuiter J. Non-steroidal Anti-inflammatory Drugs (NSAIDS). www.auburn.edu/~deruija/nsaids_2002.pdf (Accessed on 15.02. 2019)

88. Meyer M., Chudziak F.; Schwanstecher C., Schwanstecher M.; Panten U. Structural requirements of sulfonylureas and analogues for interaction with sulfonylurea receptor subtypes. Br J Pharmacol 1999, 128, 27-31

89. Pajouhesh H.; George R.;, Lenz D.R. Medicinal Chemical Properties of Successful Central Nervous System Drugs. NeuroRx 2005, 2, 541-553.

90. Audeef A. Absorption and Drug Development: Solubility, Permeability and Charge State. John Wily and Sons, Inc., Hoboken, New Jersey, USA; 2003; p 62; ISBN 0-471-42365-1

91. Levander S.; Stahle-Backdahi M.; Hagemark O. Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol 1991, 41, 435-9

92. Pagliara A.; Testa B; Carrupt P.; Jolliet P.; Morin C.; Morin D.; Urien S.; Tillement J.; Rihoux J. Molecular Properties and Pharmacokinetic Behavior of Cetirizine, a Zwitterionic H1-Receptor Antagonist. J Med Chem 1998, 41, 853–863

93. Sanguinetti M.C.; Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440, 463–9

94. Scherer C.R.; Lerche C.I.; Decher N.; Dennis A.T.; Maier P.; Ficker E.; Busch A.E.; Wollnik B.; Steinmeyer K. The antihistamine fexofenadine does not affect IKr currents in a case report of drug-induced cardiac arrhythmia. Br J Pharmacol 2002, 137, 892–900

95. Russell R.I. Non-steroidal anti-inflammatory drugs and gastrointestinal damage—problems and solutions. Postgraduate Medical Journal 2001, 77, 82-88

96. Radi Z.A.1.; Khan N.K. Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol 2006, 58, 163-73.
97. van Oijen M.G.; Dieleman J.P.; Laheij R.J.; Sturkenboom M.C.; Jansen J.B.; Verheugt F.W. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008, 6, 309-13

98. Vane J.R.; Botting R.M. The mechanism of action of aspirin. Thrombosis Research 2003, 10, 255-258

99. Sulfonylureas [http://www.people.vcu.edu/~urdesai/sulf.htm](http://www.people.vcu.edu/~urdesai/sulf.htm) (URL accessed on 20/01/2019)

100. Carroll F.I.; Brine G.A.; Boldt K.G.; Cone E.J. Yousefnejad D.; Bruce V.; Aupel D., Buchwald W.F. Phencyclidine metabolism: resolution, structure, and biological activity of the isomers of the hydroxy metabolite, 4-phenyl-4-(1-piperidinyl)cyclohexanol. J Med Chem 1981, 24, 1047-1051

101. Cook C.E.; Perez-Reyes M.; Jeffcoat A.R.; Brine D.R. Phencyclidine disposition in humans after small doses of radiolabeled drug. Fed Proc1983, 4: 2566-9

102. Huestis MA1, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995; 19, 443-9

103. Abraham T.T.; Lowe R.H.; Pirnay S.O.; Darwin W.D.; Huesti M.A. Simultaneous GC–EI-MS Determination of Δ⁹-Tetrahydrocannabinol, 11-Hydroxy-Δ⁹-Tetrahydrocannabinol, and 11-nor-9-Carboxy-Δ⁹-Tetrahydrocannabinol in Human Urine Following Tandem Enzyme-Alkaline Hydrolysis. J Anal Toxicol 2007, 41, 477-485

104. Portoghese P.; Sultana M.; Nagase H.; Takemon A.E. Application of the message-address concept in the design of highly potent and selective. Delta. Opioid receptor antagonists. J Med Chem 1988, 31, 281–282